Maria Dall'Era, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address10 Koret Way, #241
San Francisco CA 94117
Phone415-476-0783
PronounsShe/Her/Hers
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco2004Fellowship in Rheumatology
    University of California, San FranciscoResidency School of Medicine
    University of California, San FranciscoM.D.1997School of Medicine
    University of California, BerkeleyBA1993Immunology
    Collapse Awards and Honors
    UCSF2007Ira M. Goldstein Award for Outstanding Teaching in Rheumatology
    Lupus Foundation of America2014 Purple Ribbon Award
    UCSF2010Exceptional Physician Award
    UCSF2006Ephraim Engleman Award for Excellence in Arthritis Research
    American College of Rheumatology2018Edmund L. Dubois Memorial Lectureship Award
    Lupus Foundation of America2023Evelyn V. Hess Award

    Collapse Overview 
    Collapse Overview
    Maria Dall’Era is the Jean S. Engleman Distinguished Professor of Medicine and Chief of the Division of Rheumatology at the University of California, San Francisco (UCSF).

    She is Director of the UCSF Rheumatology Clinical Research Center and Lupus Clinic. She also serves as the Chair of the Lupus Clinical Investigators Network (LuCIN) and is a steering committee member of the Lupus Academy, Lupus Forum, and the Lupus 21st Century annual conference. She is the PI of a CDC-funded population- based longitudinal lupus cohort in the San Francisco Bay Area called the California Lupus Epidemiology Study and the PI on clinical trials focused on SLE and lupus nephritis.

    She completed her Medical Degree in 1997, from the University of California, San Francisco, where she later completed her Internship and Residency, and became Chief Resident and the Fellow. She has authored numerous publications in the areas of SLE and lupus nephritis. She is a co-author of the Treatment of Lupus Nephritis chapter in Up-To-Date. She received the Edmund L. Dubois Memorial Lectureship Award from the American College of Rheumatology and the Evelyn V. Hess award from the Lupus Foundation of America.

    Her research interests include systemic lupus erythematosus, lupus nephritis, novel biologic agents, lupus nephritis outcomes, and clinical trials.

    Collapse ORNG Applications 
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care Res (Hoboken). 2025 Mar 24. Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-García A, Hiraki LT, Rovin B, Son MBF, Alvarado A, Aranow C, Barnado A, Broder A, Brunner HI, Chowdhary V, Contreras G, Felix C, Ferucci ED, Gibson KL, Hersh AO, Izmirly PM, Kalunian K, Kamen D, Rollins B, Smith BJ, Thomas A, Timlin H, Wallace DJ, Ward M, Azzam M, Bartels CM, Cunha JS, DeQuattro K, Fava A, Figueroa-Parra G, Garg S, Greco J, Cuéllar-Gutiérrez MC, Iyer P, Johannemann AS, Jorge A, Kasturi S, Kawtharany H, Khawandi J, Kirou KA, Legge A, Liang KV, Lockwood MM, Sanchez-Rodriguez A, Turgunbaev M, Williams JN, Turner AS, Mustafa RA. PMID: 40127995.
      View in: PubMed   Mentions:
    2. Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network. Rheumatology (Oxford). 2025 Mar 01; 64(3):1193-1200. Carlucci PM, Preisinger K, Deonaraine KK, Zaminski D, Dall'Era M, Gold HT, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Furie R, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao D, Weisman MH, Izmirly PM, Buyon J, Petri M, Accelerating Medicines Partnership in RA/SLE Network . PMID: 38530774; PMCID: PMC11879353.
      View in: PubMed   Mentions:    Fields:    
    3. Epigenetic attenuation of interferon signaling drives aging-related improvements in systemic lupus. medRxiv. 2025 Jan 28. Narendra R, Phan HV, Patterson SL, Almonte Loya AL, Lanata C, Love C, Park J, Lydon EC, Shimoda MA, Barcellos L, Mekonen H, Detweiler A, Deosthale P, Neff N, Criswell LA, Maliskova L, Eckalbar W, Fragiadakis G, Yazdany J, Dall'Era M, Katz P, Ye CJ, Sirota M, Langelier CR. PMID: 39974140; PMCID: PMC11838985.
      View in: PubMed   Mentions:
    4. Changes in DNA methylation are associated with systemic lupus erythematosus flare remission and clinical subtypes. Clin Epigenetics. 2024 Dec 18; 16(1):181. Horton MK, Nititham J, Taylor KE, Katz P, Ye CJ, Yazdany J, Dall'Era M, Hurabielle C, Barcellos LF, Criswell LA, Lanata CM. PMID: 39696438; PMCID: PMC11656870.
      View in: PubMed   Mentions:    Fields:    
    5. Measuring Frailty in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2024 Dec 08. Katz P, Dall'Era M, Plantinga L, Barbour KE, Greenlund KJ, Yazdany J. PMID: 39648405.
      View in: PubMed   Mentions:    Fields:    
    6. Physical inactivity exacerbates pathologic inflammatory signalling at the single cell level in patients with systemic lupus. EBioMedicine. 2024 Dec; 110:105432. Patterson SL, Van Phan H, Ye CJ, Lanata C, González SC, Park J, Criswell LA, Barbour KE, Yazdany J, Dall'Era M, Sirota M, Katz P, Langelier CR. PMID: 39531917; PMCID: PMC11603005.
      View in: PubMed   Mentions:    Fields:    
    7. Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS. Lupus Sci Med. 2024 Nov 09; 11(2). Dall'Era M, Kalunian K, Solomons N, Truman M, Hodge LS, Yap E, Askanase AD. PMID: 39521453; PMCID: PMC11552023.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    8. Cell-Specific Transposable Element and Gene Expression Analysis Across Systemic Lupus Erythematosus Phenotypes. ACR Open Rheumatol. 2024 Nov; 6(11):769-779. Cutts Z, Patterson S, Maliskova L, Taylor KE, Ye CJ, Dall'Era M, Yazdany J, Criswell LA, Fragiadakis GK, Langelier C, Capra JA, Sirota M, Lanata CM. PMID: 39143499; PMCID: PMC11557995.
      View in: PubMed   Mentions:
    9. Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis of the Control Arms of Randomized Controlled Trials. Arthritis Rheumatol. 2024 Sep; 76(9):1408-1418. Figueroa-Parra G, Cuéllar-Gutiérrez MC, González-Treviño M, Sanchez-Rodriguez A, Flores-Gouyonnet J, Meade-Aguilar JA, Prokop LJ, Murad MH, Dall'Era M, Rovin BH, Houssiau F, Tamirou F, Fervenza FC, Crowson CS, Putman MS, Duarte-García A. PMID: 38766897.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations. Lupus Sci Med. 2024 May 22; 11(1). Askanase AD, Furie RA, Dall'Era M, Bomback AS, Schwarting A, Zhao MH, Bruce IN, Khamashta M, Rubin B, Carroll A, Daniels M, Levy RA, van Vollenhoven R, Urowitz MB. PMID: 38777595; PMCID: PMC11116871.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history. Lupus Sci Med. 2024 May 15; 11(1). DeQuattro K, Trupin L, Patterson S, Rush S, Gordon C, Greenlund KJ, Barbour KE, Lanata C, Criswell LA, Dall'Era M, Yazdany J, Katz PP. PMID: 38754905; PMCID: PMC11097884.
      View in: PubMed   Mentions:    Fields:    
    12. Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. bioRxiv. 2024 Mar 09. Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, Guthridge J, Hoover PJ, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, Furie R, Belmont M, Izmirly P, Clancy R, Hildeman D, Woodle ES, Apruzzese W, McMahon MA, Grossman J, Barnas JL, Payan-Schober F, Ishimori M, Weisman M, Kretzler M, Berthier CC, Hodgin JB, Demeke DS, Putterman C, Accelerating Medicines Partnership: RA/SLE Network, Brenner MB, Anolik JH, Raychaudhuri S, Hacohen N, James JA, Davidson A, Petri MA, Buyon JP, Diamond B, Zhang F, Lederer JA, Rao DA. PMID: 38293222; PMCID: PMC10827101.
      View in: PubMed   Mentions: 1  
    13. Screening of Environmental Chemicals to Characterize Exposures in Participants With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2024 Jun; 76(6):905-918. Lanata CM, Taylor KE, Hurst-Hopf J, Nititham J, Blazer A, Trupin L, Katz P, Dall'Era M, Yazdany J, Chung SA, Abrahamsson D, Gerona R, Criswell LA. PMID: 38129991; PMCID: PMC11136608.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    14. Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network. Arthritis Res Ther. 2024 02 20; 26(1):54. Izmirly PM, Kim MY, Carlucci PM, Preisinger K, Cohen BZ, Deonaraine K, Zaminski D, Dall'Era M, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao DA, Weisman MH, Accelerating Medicines Partnership in RA/SLE Network, Petri M, Buyon J, Furie R. PMID: 38378664; PMCID: PMC10877793.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity. Ann Rheum Dis. 2024 Feb 15; 83(3):404-406. Yelnik CM, Xie X, Guerra MM, Costedoat-Chalumeau N, Khosroshahi A, Kamen DL, Schwartz N, Katz P, Minett M, Amoss RT, Fu A, Guettrot-Imbert G, Lazaro E, Le Guern V, Oates J, Dall'Era M, Yazdany J, Molto A, Kim MY, Salmon JE. PMID: 37875285; PMCID: PMC10922457.
      View in: PubMed   Mentions: 1     Fields:    
    16. Local Ancestry at the Major Histocompatibility Complex Region is Not a Major Contributor to Disease Heterogeneity in a Multiethnic Lupus Cohort. Arthritis Rheumatol. 2024 Apr; 76(4):614-619. Solomon O, Lanata CM, Adams C, Nititham J, Taylor KE, Chung SA, Yazdany J, Dall'Era M, Pons-Estel BA, Tusié-Luna T, Tsao B, Morand E, Alarcón-Riquelme ME, Barcellos LF, Criswell LA. PMID: 38073021; PMCID: PMC10965360.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. Lancet Rheumatol. 2024 Mar; 6(3):e168-e177. Chakravarty EF, Utset T, Kamen DL, Contreras G, McCune WJ, Aranow C, Kalunian K, Massarotti E, Clowse MEB, Rovin BH, Lim SS, Majithia V, Dall'Era M, Looney RJ, Erkan D, Saxena A, Olsen NJ, Ko K, Guthridge JM, Goldmuntz E, Springer J, D'Aveta C, Keyes-Elstein L, Barry B, Pinckney A, McNamara J, James JA. PMID: 38301682; PMCID: PMC10922882.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight. 2024 Jan 23; 9(2). Fava A, Buyon J, Magder L, Hodgin J, Rosenberg A, Demeke DS, Rao DA, Arazi A, Celia AI, Putterman C, Anolik JH, Barnas J, Dall'Era M, Wofsy D, Furie R, Kamen D, Kalunian K, James JA, Guthridge J, Atta MG, Monroy Trujillo J, Fine D, Clancy R, Belmont HM, Izmirly P, Apruzzese W, Goldman D, Berthier CC, Hoover P, Hacohen N, Raychaudhuri S, Davidson A, Diamond B, Accelerating Medicines Partnership in RA/SLE network, Petri M. PMID: 38258904; PMCID: PMC10906224.
      View in: PubMed   Mentions: 4     Fields:    
    19. Economic insecurities and patient-reported outcomes in patients with systemic lupus erythematosus in the USA: a cross-sectional analysis of data from the California Lupus Epidemiology Study. Lancet Rheumatol. 2024 Feb; 6(2):e105-e114. Sandoval-Heglund D, Roberts E, Park J, Dall'Era M, Lanata C, Barbour KE, Greenlund KJ, Gordon C, Katz PP, Yazdany J. PMID: 38267097; PMCID: PMC10964913.
      View in: PubMed   Mentions: 2     Fields:    
    20. Cell-Specific Transposable Element Gene Expression Analysis Identifies Associations with Systemic Lupus Erythematosus Phenotypes. bioRxiv. 2023 Nov 28. Cutts Z, Patterson S, Maliskova L, Taylor KE, Ye C, Dall'Era M, Yazdany J, Criswell L, Fragiadakis GK, Langelier C, Capra JA, Sirota M, Lanata CM. PMID: 38076936; PMCID: PMC10705239.
      View in: PubMed   Mentions:
    21. Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry. RMD Open. 2023 09; 9(3). Rector I, Owen KA, Bachali P, Hubbard E, Yazdany J, Dall'era M, Grammer AC, Lipsky PE. PMID: 37709528; PMCID: PMC10503349.
      View in: PubMed   Mentions: Translation:HumansCells
    22. The association of trauma with self-reported flares and disease activity in systemic lupus erythematosus (SLE). Rheumatology (Oxford). 2023 08 01; 62(8):2780-2788. Katz P, Patterson SL, DeQuattro K, Lanata CM, Barbour KE, Greenlund KJ, Gordon C, Criswell LA, Dall'Era M, Yazdany J. PMID: 36477308; PMCID: PMC10544732.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE. Lupus Sci Med. 2023 Jul; 10(2). Askanase AD, Aranow C, Kim MY, Kamen DL, Arriens C, Khalili L, Tang W, Barasch J, Dall'Era M, Mackay M. PMID: 37429672; PMCID: PMC10335468.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    24. Medication Cost Concerns and Disparities in Patient-Reported Outcomes Among a Multiethnic Cohort of Patients With Systemic Lupus Erythematosus. J Rheumatol. 2023 10; 50(10):1302-1309. Aguirre A, DeQuattro K, Shiboski S, Katz P, Greenlund KJ, Barbour KE, Gordon C, Lanata C, Criswell LA, Dall'Era M, Yazdany J. PMID: 37321640; PMCID: PMC10543599.
      View in: PubMed   Mentions: 1     Fields:    
    25. Non-Full House Membranous Lupus Nephritis Represents a Clinically Distinct Subset. Kidney360. 2023 07 01; 4(7):935-942. Ye J, Croom N, Troxell ML, Kambham N, Zuckerman JE, Andeen N, Dall'Era M, Hsu R, Walavalkar V, Laszik ZG, Urisman A. PMID: 37257088; PMCID: PMC10371271.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    26. The use of combination monoclonal antibody therapies in lupus-where are we now? Rheumatology (Oxford). 2023 May 02; 62(5):1724-1729. Rua J, Dall'Era M, Isenberg D. PMID: 36106990.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Molecular pathways identified from single nucleotide polymorphisms demonstrate mechanistic differences in systemic lupus erythematosus patients of Asian and European ancestry. Sci Rep. 2023 04 01; 13(1):5339. Owen KA, Bell KA, Price A, Bachali P, Ainsworth H, Marion MC, Howard TD, Langefeld CD, Shen N, Yazdany J, Dall'era M, Grammer AC, Lipsky PE. PMID: 37005464; PMCID: PMC10067935.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    28. Perceived Stress and Prediction of Worse Disease Activity and Symptoms in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort. Arthritis Care Res (Hoboken). 2023 08; 75(8):1681-1689. Patterson S, Trupin L, Hartogensis W, DeQuattro K, Lanata C, Gordon C, Barbour KE, Greenlund KJ, Dall'Era M, Yazdany J, Katz P. PMID: 36537191; PMCID: PMC10279800.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial. ACR Open Rheumatol. 2023 Jan; 5(1):38-48. Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, Le Bolay C, Drouin EE, Kao AH, Guehring H, Dall'Era M. PMID: 36530019; PMCID: PMC9837396.
      View in: PubMed   Mentions: 11  
    30. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology (Oxford). 2022 11 02; 61(11):4335-4343. Carlucci PM, Li J, Fava A, Deonaraine KK, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, DeJager W, Guthridge JM, Haag K, Rao DA, Brenner MB, Lederer JA, Apruzzese W, Belmont HM, Izmirly PM, Zaminski D, Wu M, Connery S, Payan-Schober F, Furie R, Dall'Era M, Cho K, Kamen D, Kalunian K, Anolik J, Barnas J, Ishimori M, Weisman MH, Accelerating Medicines Partnership (AMP) RA/SLE Network, Buyon JP, Petri M. PMID: 35212719; PMCID: PMC9629353.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    31. Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States. J Manag Care Spec Pharm. 2023 Jan; 29(1):36-45. Dall'Era M, Kalunian K, Eaddy M, Ogbonnaya A, Farrelly E, Turowski E, Birardi V, Solomons N, Randhawa S, Mina-Osorio P. PMID: 36190835; PMCID: PMC10657222.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    32. Causes of Death Among Individuals With Systemic Lupus Erythematosus by Race and Ethnicity: A Population-Based Study. Arthritis Care Res (Hoboken). 2023 01; 75(1):61-68. Taylor T, Anastasiou C, Ja C, Rush S, Trupin L, Dall'Era M, Katz P, Barbour KE, Greenlund KJ, Yazdany J, Gianfrancesco MA. PMID: 35904969; PMCID: PMC9797422.
      View in: PubMed   Mentions: 8     Fields:    
    33. Dynamics of Methylation of CpG Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort. Arthritis Rheumatol. 2022 10; 74(10):1676-1686. Lanata CM, Nititham J, Taylor KE, Solomon O, Chung SA, Blazer A, Trupin L, Katz P, Dall'Era M, Yazdany J, Sirota M, Barcellos LF, Criswell LA. PMID: 35635730; PMCID: PMC9529797.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    34. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol. 2022; 13:980079. Kirou KA, Dall Era M, Aranow C, Anders HJ. PMID: 36119023; PMCID: PMC9472122.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    35. Race, Ethnicity, and Disparities in the Risk of End-Organ Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort. Arthritis Care Res (Hoboken). 2023 01; 75(1):34-43. Aguirre A, Izadi Z, Trupin L, Barbour KE, Greenlund KJ, Katz P, Lanata C, Criswell L, Dall'Era M, Yazdany J. PMID: 35452566; PMCID: PMC9587136.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    36. Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 11; 74(11):1822-1828. Urowitz MB, Aranow C, Asukai Y, Bass DL, Bruce IN, Chauhan D, Dall'Era M, Furie R, Fox NL, Gilbride JA, Hammer A, Ginzler EM, Gonzalez-Rivera T, Levy RA, Merrill JT, Quasny H, Roth DA, Stohl W, van Vollenhoven R, Wallace DJ, Petri M. PMID: 35439360; PMCID: PMC9805003.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    37. The Impact of Telemedicine on Rheumatology Care. Front Med (Lausanne). 2022; 9:876835. Tang W, Inzerillo S, Weiner J, Khalili L, Barasch J, Gartshteyn Y, Dall'Era M, Aranow C, Mackay M, Askanase A. PMID: 35669922; PMCID: PMC9163385.
      View in: PubMed   Mentions: 2  
    38. Physical Inactivity and Incident Depression in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort. Arthritis Care Res (Hoboken). 2022 07; 74(7):1098-1104. Patterson SL, Trupin L, Yazdany J, Dall'Era M, Lanata C, Dequattro K, Hartogensis W, Katz P. PMID: 33421358; PMCID: PMC9829076.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    39. High Disease Severity Among Asian Patients in a US Multiethnic Cohort of Individuals With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 06; 74(6):896-903. DeQuattro K, Trupin L, Murphy LB, Rush S, Criswell LA, Lanata CM, Dall'Era M, Katz P, Yazdany J. PMID: 33337580; PMCID: PMC8211905.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. Science. 2022 04 08; 376(6589):eabf1970. Perez RK, Gordon MG, Subramaniam M, Kim MC, Hartoularos GC, Targ S, Sun Y, Ogorodnikov A, Bueno R, Lu A, Thompson M, Rappoport N, Dahl A, Lanata CM, Matloubian M, Maliskova L, Kwek SS, Li T, Slyper M, Waldman J, Dionne D, Rozenblatt-Rosen O, Fong L, Dall'Era M, Balliu B, Regev A, Yazdany J, Criswell LA, Zaitlen N, Ye CJ. PMID: 35389781; PMCID: PMC9297655.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansCells
    41. A glimpse into the future of systemic lupus erythematosus. Ther Adv Musculoskelet Dis. 2022; 14:1759720X221086719. Aringer M, Alarcón-Riquelme ME, Clowse M, Pons-Estel GJ, Vital EM, Dall'Era M. PMID: 35368371; PMCID: PMC8972918.
      View in: PubMed   Mentions: 8  
    42. Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Sci Med. 2022 Mar; 9(1). van Vollenhoven R, Askanase AD, Bomback AS, Bruce IN, Carroll A, Dall'Era M, Daniels M, Levy RA, Schwarting A, Quasny HA, Urowitz MB, Zhao MH, Furie R. PMID: 35346982; PMCID: PMC8961173.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    43. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol. 2022 Apr; 4(4):e282-e292. Morand EF, Furie RA, Bruce IN, Vital EM, Dall'Era M, Maho E, Pineda L, Tummala R. PMID: 38288923.
      View in: PubMed   Mentions: 18     Fields:    
    44. Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies. Arthritis Care Res (Hoboken). 2022 03; 74(3):420-426. Williams JN, Dall'Era M, Lim SS, Feldman CH, Arntsen KA, Blazer AD, Goode T, Merrill JT, Sheikh S, Stevens AM, Lipsky PE, Costenbader KH. PMID: 33026693; PMCID: PMC9113543.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    45. Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. Lupus Sci Med. 2021 Dec; 8(1). Izmirly PM, Ferucci ED, Somers EC, Wang L, Lim SS, Drenkard C, Dall'Era M, McCune WJ, Gordon C, Helmick C, Parton H. PMID: 34921094; PMCID: PMC8685969.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    46. Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Sci Med. 2021 08; 8(1). Deonaraine KK, Carlucci PM, Fava A, Li J, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, Haag K, Rao DA, Apruzzese W, Belmont HM, Izmirly PM, Wu M, Connery S, Payan-Schober F, Furie RA, Berthier CC, Dall'Era M, Cho K, Kamen DL, Kalunian K, Anolik J, Ishimori M, Weisman MH, Accelerating Medicines Partnership RA/SLE network, Petri MA, Buyon JP. PMID: 34389634; PMCID: PMC8354250.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    47. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021 Jun; 73(6):991-996. Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, Ferucci ED, Dall'Era M, Gordon C, Helmick CG, Somers EC. PMID: 33474834; PMCID: PMC8169527.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    48. Transcriptomic analysis of immune cells in a multi-ethnic cohort of systemic lupus erythematosus patients identifies ethnicity- and disease-specific expression signatures. Commun Biol. 2021 04 21; 4(1):488. Andreoletti G, Lanata CM, Trupin L, Paranjpe I, Jain TS, Nititham J, Taylor KE, Combes AJ, Maliskova L, Ye CJ, Katz P, Dall'Era M, Yazdany J, Criswell LA, Sirota M. PMID: 33883687; PMCID: PMC8060402.
      View in: PubMed   Mentions: 10  Translation:HumansCells
    49. Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic/Latino Persons - California, 2007-2017. MMWR Morb Mortal Wkly Rep. 2021 Feb 19; 70(7):236-239. Gianfrancesco MA, Dall'Era M, Murphy LB, Helmick CG, Li J, Rush S, Trupin L, Yazdany J. PMID: 33600382; PMCID: PMC7891689.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    50. Impact of Limited Health Literacy on Patient-Reported Outcomes in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2021 01; 73(1):110-119. Katz P, Dall'Era M, Trupin L, Rush S, Murphy LB, Lanata C, Criswell LA, Yazdany J. PMID: 32741118; PMCID: PMC7775267.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    51. Major Depression and Adverse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Results From a Prospective Longitudinal Cohort. Arthritis Care Res (Hoboken). 2021 01; 73(1):48-54. Dietz B, Katz P, Dall'Era M, Murphy LB, Lanata C, Trupin L, Criswell LA, Yazdany J. PMID: 32741124; PMCID: PMC7775294.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    52. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol. 2021 01; 73(1):121-131. Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. PMID: 32755035; PMCID: PMC7839443.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    53. A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology (Oxford). 2020 07 01; 59(7):1505-1513. Aranow C, Cush J, Bolster MB, Striebich CC, Dall'era M, Mackay M, Olech E, Frech T, Box J, Keating R, Wasko MC, St Clair W, Kivitz A, Huang W, Ricketts P, Welch B, Callahan S, Spychala M, Boyle K, York K, Keyes-Elstein L, Goldmuntz E, Diamond B, Davidson A. PMID: 31628482; PMCID: PMC7310095.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    54. Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney Int Rep. 2020 Aug; 5(8):1302-1305. Almaani S, Bhatt U, Arriens C, Bonfa E, Dall'Era M, Houssiau F, Kalunian K, Mackay M, Sanchez-Guerrero J, Solomons N, Rovin BH. PMID: 32775830; PMCID: PMC7403554.
      View in: PubMed   Mentions:
    55. Quality of Care for the Screening, Diagnosis, and Management of Lupus Nephritis Across Multiple Health Care Settings. Arthritis Care Res (Hoboken). 2020 07; 72(7):888-896. Aggarwal I, Li J, Trupin L, Gaynon L, Katz PP, Lanata C, Criswell L, Murphy LB, Dall'Era M, Yazdany J. PMID: 31058460; PMCID: PMC6832767.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    56. Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project. Arthritis Care Res (Hoboken). 2020 05; 72(5):622-629. Maningding E, Dall'Era M, Trupin L, Murphy LB, Yazdany J. PMID: 31115180; PMCID: PMC6872905.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansPHPublic Health
    57. Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020 04; 72(4):525-533. DeQuattro K, Trupin L, Li J, Katz PP, Murphy LB, Yelin EH, Rush S, Lanata C, Criswell LA, Dall'Era M, Yazdany J. PMID: 31069933; PMCID: PMC6842031.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    58. Author Correction: A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nat Commun. 2020 02 27; 11(1):1164. Lanata CM, Paranjpe I, Nititham J, Taylor KE, Gianfrancesco M, Paranjpe M, Andrews S, Chung SA, Rhead B, Barcellos LF, Trupin L, Katz P, Dall'Era M, Yazdany J, Sirota M, Criswell LA. PMID: 32109229; PMCID: PMC7046614.
      View in: PubMed   Mentions:    Fields:    
    59. A Mobile Learning Module to Support Interprofessional Knowledge Construction in the Health Professions. Am J Pharm Educ. 2020 02; 84(2):847519. Floren LC, Mandal J, Dall'Era M, Shin J, Irby DM, Cate OT, O'Brien BC. PMID: 32226076; PMCID: PMC7092784.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    60. Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus. ACR Open Rheumatol. 2020 Jan; 2(1):53-60. Katz P, Pedro S, Alemao E, Yazdany J, Dall'Era M, Trupin L, Rush S, Michaud K. PMID: 31943975; PMCID: PMC6957915.
      View in: PubMed   Mentions: 16  
    61. Psychometric Evaluation of the National Institutes of Health Patient-Reported Outcomes Measurement Information System in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort. Arthritis Care Res (Hoboken). 2019 12; 71(12):1630-1639. Katz P, Yazdany J, Trupin L, Rush S, Helmick CG, Murphy LB, Lanata C, Criswell LA, Dall'Era M. PMID: 30354017; PMCID: PMC6482092.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    62. Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019 Oct; 20(10):1404. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B, Accelerating Medicines Partnership in SLE network. PMID: 31409923.
      View in: PubMed   Mentions: 4     Fields:    
    63. A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nat Commun. 2019 08 29; 10(1):3902. Lanata CM, Paranjpe I, Nititham J, Taylor KE, Gianfrancesco M, Paranjpe M, Andrews S, Chung SA, Rhead B, Barcellos LF, Trupin L, Katz P, Dall'Era M, Yazdany J, Sirota M, Criswell LA. PMID: 31467281; PMCID: PMC6715644.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    64. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019 07; 20(7):902-914. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B, Accelerating Medicines Partnership in SLE network. PMID: 31209404; PMCID: PMC6726437.
      View in: PubMed   Mentions: 342     Fields:    Translation:HumansCells
    65. Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. PLoS Med. 2019 05; 16(5):e1002800. Singh JA, Fraenkel L, Green C, Alarcón GS, Barton JL, Saag KG, Hanrahan LM, Raymond SC, Kimberly RP, Leong AL, Reyes E, Street RL, Suarez-Almazor ME, Eakin GS, Marrow L, Morgan CJ, Caro B, Sloan JA, Jandali B, Garcia SR, Grossman J, Winthrop KL, Trupin L, Dall'Era M, Meara A, Rizvi T, Chatham WW, Yazdany J. PMID: 31067237; PMCID: PMC6505936.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    66. Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis. Lupus Sci Med. 2019; 6(1):e000308. Gomez Mendez LM, Cascino MD, Katsumoto TR, Brakeman P, Brunetta P, Jayne D, Dall'Era M, Rovin B, Garg J. PMID: 31080631; PMCID: PMC6485211.
      View in: PubMed   Mentions: 3     Fields:    
    67. Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis Rheumatol. 2019 03; 71(3):411-419. Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, Levy DM, Silverman E, Petri M, Arriens C, Lewis EJ, Korbet SM, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan TM, Rathi M, Gupta KL, Jha V, Hasni S, West MR, Solomons N, Houssiau FA, Romero-Diaz J, Mejia-Vilet J, Rovin BH. PMID: 30225865.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    68. Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 03; 71(3):431-440. Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD, Autoimmunity Centers of Excellence. PMID: 30277008; PMCID: PMC6447289.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCells
    69. Current challenges in the development of new treatments for lupus. Ann Rheum Dis. 2019 06; 78(6):729-735. Dall'Era M, Bruce IN, Gordon C, Manzi S, McCaffrey J, Lipsky PE. PMID: 30636212.
      View in: PubMed   Mentions: 15     Fields:    
    70. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Ann Rheum Dis. 2019 07; 78(7):1004-1006. Sciascia S, Yazdany J, Dall'Era M, Fenoglio R, Radin M, Aggarwal I, Cuadrado MJ, Schreiber K, Barreca A, Papotti M, Roccatello D. PMID: 30552172; PMCID: PMC6565439.
      View in: PubMed   Mentions: 5     Fields:    
    71. Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clin J Am Soc Nephrol. 2018 10 08; 13(10):1502-1509. Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall'Era M, Looney RJ, Rovin B, Dragone L, Brunetta P. PMID: 30089664; PMCID: PMC6218830.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    72. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med. 2018; 5(1):e000258. Merrill JT, Manzi S, Aranow C, Askanase A, Bruce I, Chakravarty E, Chong B, Costenbader K, Dall'Era M, Ginzler E, Hanrahan L, Kalunian K, Merola J, Raymond S, Rovin B, Saxena A, Werth VP. PMID: 29657738; PMCID: PMC5894527.
      View in: PubMed   Mentions: 28     Fields:    
    73. The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. Arthritis Rheumatol. 2017 Oct; 69(10):1996-2005. Dall'Era M, Cisternas MG, Snipes K, Herrinton LJ, Gordon C, Helmick CG. PMID: 28891237.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    74. Treatment of lupus nephritis: current paradigms and emerging strategies. Curr Opin Rheumatol. 2017 05; 29(3):241-247. Dall'Era M. PMID: 28207493.
      View in: PubMed   Mentions: 13  Translation:HumansCells
    75. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017 Aug; 37(8):1249-1255. Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, Dall'Era M. PMID: 28258475.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    76. Mapping Perceptions of Lupus Medication Decision-Making Facilitators: The Importance of Patient Context. Arthritis Care Res (Hoboken). 2016 12; 68(12):1787-1794. Qu H, Shewchuk RM, Alarcón G, Fraenkel L, Leong A, Dall'Era M, Yazdany J, Singh JA. PMID: 27059939.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    77. Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus. J Immunol. 2016 10 01; 197(7):2854-63. Doedens JR, Jones WD, Hill K, Mason MJ, Gersuk VH, Mease PJ, Dall'Era M, Aranow C, Martin RW, Cohen SB, Fleischmann RM, Kivitz AJ, Burge DJ, Chaussabel D, Elkon KB, Posada JA. PMID: 27534558.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    78. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015; 2(1):e000123. Tamirou F, Lauwerys BR, Dall'Era M, Mackay M, Rovin B, Cervera R, Houssiau FA, MAINTAIN Nephritis Trial Investigators. PMID: 26629352; PMCID: PMC4654096.
      View in: PubMed   Mentions: 68     Fields:    
    79. Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique. J Rheumatol. 2015 Sep; 42(9):1616-23. Singh JA, Qu H, Yazdany J, Chatham W, Dall'era M, Shewchuk RM. PMID: 26178276.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    80. Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015 Jul; 67(7):1848-57. Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B. PMID: 25777546; PMCID: PMC4732716.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    81. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med. 2015; 2(1):e000089. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. PMID: 26023331; PMCID: PMC4442174.
      View in: PubMed   Mentions: 15     Fields:    
    82. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015 May; 67(5):1305-13. Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M. PMID: 25605554.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    83. A young woman with systemic lupus erythematosus and extensive mesenteric vasculitis involving small and medium vessels. Arthritis Care Res (Hoboken). 2012 Dec; 64(12):1928-33. Ashouri JF, Davis JL, Farkas A, Durack JC, Ramachandran R, Dall'Era M. PMID: 22933330.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    84. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2011 Sep; 23(5):454-8. Dall'Era M. PMID: 21720247.
      View in: PubMed   Mentions: 13  Translation:Humans
    85. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep. 2011 Aug; 13(4):308-16. Dall'era M, Chakravarty EF. PMID: 21584692; PMCID: PMC4400849.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    86. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011 Aug; 63(8):1170-7. Yazdany J, Trupin L, Gansky SA, Dall'era M, Yelin EH, Criswell LA, Katz PP. PMID: 21584946; PMCID: PMC3149719.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    87. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011 Mar; 63(3):351-7. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. PMID: 21080348.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    88. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2010; 12(2):R48. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'Era M, Gross JA. PMID: 20302641; PMCID: PMC2888197.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    89. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Nat Rev Rheumatol. 2010 Mar; 6(3):124-5. Dall'Era M, Wofsy D. PMID: 20197774.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    90. Biologic therapy for systemic lupus erythematosus. Discov Med. 2010 Jan; 9(44):20-3. Dall'Era M, Wofsy D. PMID: 20102681.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    91. Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol. 2009 Jun; 5(6):348-51. Dall'Era M, Wofsy D. PMID: 19491915.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    92. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. PMID: 18050206.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCellsCTClinical Trials
    93. Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum. 2007 Apr 15; 57(3):538-42. Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J. PMID: 17394185.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    94. Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol. 2006 Sep; 18(5):476-80. Dall'Era M, Wofsy D. PMID: 16896285.
      View in: PubMed   Mentions: 7  Translation:Humans
    95. Systemic lupus erythematosus. How to manage, when to refer. Postgrad Med. 2003 Nov; 114(5):31-7, 40. Dall'Era M, Davis JC. PMID: 14650091.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Maria's Networks
    Concepts (275)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (50)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.